文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗银屑病、PsA和AS患者恶性肿瘤风险:临床试验与上市后监测数据整合分析(随访长达5年)

The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.
PubMed 文献 · Br J Dermatol · 2021-06-08

结论认为司库奇尤单抗治疗5年内恶性肿瘤风险低,支持长期使用。

核心结论

  • 在这项大型安全性分析中,司库奇尤单抗治疗长达5年的恶性肿瘤风险低。
  • 这些数据支持司库奇尤单抗在银屑病、PsA和AS这些适应症中的长期使用。

研究设计与样本

  • 整合安全性分析,纳入司库奇尤单抗临床试验项目与上市后安全性监测数据。
  • 纳入任何接受至少一个获批剂量司库奇尤单抗的患者,最长随访5年。
  • 采用暴露调整发生率(EAIR;每100患者治疗年)评估恶性肿瘤发生率。
  • 使用SEER数据库作为参考人群报告标准化发病比(SIR),并报告上市后监测的粗累积发生率。

临床怎么用

  • 对于适合司库奇尤单抗治疗的银屑病、PsA和AS患者,长达5年的治疗中恶性肿瘤风险低,支持长期使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long-term robust studies. OBJECTIVES: To assess the malignancy risk in patients with secukinumab-treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). METHODS: This integrated safety analysis from both the secukinumab clinical trial programme and postmarketing safety surveillance data included any patient receiving at least one approved dose of secukinumab with a maximum of 5 years of follow-up. Safety analyses evaluated the rate of malignancy using exposure-adjusted incidence rates [EAIR; incidence rates per 100 patient treatment-years (PTY)]. Standardized incidence ratios (SIRs) were reported using the Surveillance, Epidemiology, and End Results Program (SEER) database as a reference population. Crude incidence of malignancy was also reported using postmarketing surveillance data. RESULTS: Safety data from 49 clinical trials with secukinumab-treated patients were included: 10 685 patients with psoriasis, 2523 with PsA and 1311 with AS. Across indications over a 5-year period, the EAIR of malignancy was 0·85 per 100 PTY [95% confidence interval (CI) 0·74-0·98] in secukinumab-treated patients, corresponding to 204 patients per 23 908 PTY. Overall, the observed vs. expected number of malignancies from secukinumab clinical trial data were comparable, as indicated by an SIR of 0·99 (95% CI 0·82-1·19) across indications. The estimated crude cumulative incidence reporting rate per 100 PTY for malignancy was 0·27 in the postmarketing surveillance data across indications with a cumulative exposure of 285 811 PTY. CONCLUSIONS: In this large safety analysis, the risk of malignancy was low for up to 5 years of secukinumab treatment. These data support the long-term use of secukinumab in these indications.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Lebwohl M, Deodhar A, Griffiths CEM, et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021. PMID: 33829482. doi:10.1111/bjd.20136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。